A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

NCT03289962 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

272

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Non-Small Cell Lung Cancer
Bladder Cancer
Colorectal Cancer
Triple Negative Breast Cancer
Renal Cancer
Head and Neck Cancer
Other Solid Cancers

Interventions

DRUG: Autogene cevumeran
DRUG: Atezolizumab

Sponsor

Genentech, Inc.

Collaborators

[object Object]